Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$269K Sell
11,154
-113,108
-91% -$2.96M 0.13% 108
2026
Q1
$3.49M Buy
124,262
+4,584
+4% +$122K 1.7% 27
2025
Q4
$2.98M Buy
119,678
+15,660
+15% +$395K 1.52% 32
2025
Q3
$2.65M Sell
104,018
-3,220
-3% -$79.5K 1.43% 38
2025
Q2
$2.6M Sell
107,238
-3,553
-3% -$82.9K 1.51% 34
2025
Q1
$2.81M Buy
110,791
+20,406
+23% +$534K 1.67% 26
2024
Q4
$2.4M Sell
90,385
-14,585
-14% -$396K 1.56% 27
2024
Q3
$3.04M Buy
104,970
+4,200
+4% +$123K 2% 17
2024
Q2
$2.82M Buy
100,770
+6,563
+7% +$181K 2.01% 17
2024
Q1
$2.61M Buy
94,207
+24,331
+35% +$675K 1.84% 25
2023
Q4
$2.01M Buy
69,876
+11,689
+20% +$353K 1.53% 32
2023
Q3
$1.87M Buy
58,187
+11,625
+25% +$411K 1.63% 28
2023
Q2
$1.67M Buy
46,562
+495
+1% +$19.3K 1.47% 33
2023
Q1
$1.88M Buy
46,067
+3,020
+7% +$130K 1.71% 28
2022
Q4
$2.21M Sell
43,047
-720
-2% -$34.5K 2.01% 24
2022
Q3
$1.92M Sell
43,767
-4,035
-8% -$196K 1.9% 23
2022
Q2
$2.51M Buy
47,802
+2,025
+4% +$103K 2.29% 17
2022
Q1
$2.28M Buy
45,777
+1,090
+2% +$56.6K 1.86% 22
2021
Q4
$2.64M Buy
+44,687
New +$2.21M 2.35% 13

Other funds holding PFE

Apricus Wealth's PFE Position: Q2 2026 in Review

Apricus Wealth reduced its Pfizer (PFE) stake by 91% in Q2 2026, selling an estimated $2.96M and leaving 11,154 shares worth $269K. The position accounts for 0.13% of the portfolio, ranked #108.

Apricus Wealth first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.49M in Q1 2026. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Apricus Wealth held 11,154 shares of Pfizer worth $269K as of Q2 2026.
  • Apricus Wealth sold 113,108 Pfizer shares in Q2 2026, an estimated $2.96M.
  • Pfizer made up 0.13% of Apricus Wealth's portfolio in Q2 2026, its #108 holding.
  • Apricus Wealth first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
  • Apricus Wealth's Pfizer position peaked at $3.49M in Q1 2026.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Apricus Wealth's 13F filing for Q2 2026, filed 22 Jul 2026.